Prolonged aPTT in Von Willebrand Disease
A prolonged aPTT in VWD is common but not universal—it occurs primarily when Factor VIII levels are reduced below ~0.40 IU/mL, which happens in type 2N and type 3 VWD, but aPTT is often normal in type 1 and most type 2 variants where Factor VIII remains adequate.
Understanding the aPTT-VWD Relationship
The aPTT prolongation in VWD is indirect—it reflects low Factor VIII levels, not VWF itself. Since VWF stabilizes Factor VIII in circulation, severe VWF deficiency leads to accelerated Factor VIII degradation and subsequent aPTT prolongation 1.
When aPTT is Prolonged in VWD:
- Type 3 VWD: Nearly always prolonged (FVIII <0.10 IU/mL) 1
- Type 2N VWD: Frequently prolonged (FVIII 0.05-0.40 IU/mL) 1
- Severe Type 1 VWD: May be prolonged if FVIII drops significantly
- Mild-Moderate Type 1 and Type 2A/2B/2M: Usually normal aPTT
Diagnostic Sensitivity Limitations
The aPTT is NOT a reliable screening test for VWD—while one study showed 100% sensitivity for isolated VWF deficiency 2, this applies only to severe cases with low Factor VIII. The aPTT will miss:
- Most type 1 VWD patients (VWF 0.30-0.50 IU/mL with normal FVIII)
- Type 2A, 2B, 2M variants with preserved FVIII levels
- Low VWF states
Evaluation Algorithm When aPTT is Prolonged
When encountering prolonged aPTT with bleeding history:
Measure Factor VIII activity (FVIII:C)
- If reduced: Proceed to VWF testing
- If normal: Consider other causes (lupus anticoagulant, Factor XI/XII deficiency, heparin)
VWF Testing Panel 1:
- VWF:Ag (antigen level)
- VWF activity (ristocetin cofactor or collagen binding)
- VWF:FVIII binding assay if Type 2N suspected (low FVIII with normal/near-normal VWF)
Interpret Results 1:
- Type 3: VWF:Ag and activity <0.05 IU/mL, FVIII <0.10 IU/mL
- Type 2N: VWF normal/slightly low, FVIII 0.05-0.40 IU/mL, abnormal VWF:FVIII binding
- Severe Type 1: VWF:Ag and activity <0.30 IU/mL, proportionally low FVIII
Additional Testing:
Critical Pitfalls to Avoid
Timing matters: VWF is an acute phase reactant—avoid testing during:
- Active bleeding or recent hemorrhage
- Pregnancy (VWF rises significantly)
- Acute stress, infection, or inflammation
- Estrogen therapy
Test when patient is at physiologic baseline; repeat testing is often required for diagnosis 1.
Don't assume normal aPTT excludes VWD—the majority of VWD patients have normal aPTT 2, 4. A bleeding history with normal aPTT still warrants VWF testing if clinical suspicion exists.
Blood group O patients have ~25-30% lower VWF levels physiologically—this is NOT VWD but may confound interpretation 4.
Management Implications
The prolonged aPTT itself doesn't change VWD management—treatment is based on:
- VWD type and severity
- Bleeding phenotype
- Specific clinical scenario (surgery, menorrhagia, etc.)
However, significantly prolonged aPTT (>1.5x normal) with low Factor VIII requires Factor VIII replacement (not just desmopressin) for hemostatic challenges, particularly in type 2N and type 3 VWD 1.
Current Guideline Framework
The 2021 ASH/ISTH/NHF/WFH guidelines remain current as of 2025 5. Key diagnostic thresholds 1:
- Type 1 VWD diagnosis: VWF:Ag and/or activity <0.30 IU/mL
- With abnormal bleeding: VWF <0.50 IU/mL confirms diagnosis
- Type 3: VWF <0.05 IU/mL, FVIII <0.10 IU/mL
The distinction of "low VWF" (0.30-0.50 IU/mL) was removed to reduce barriers to care, though this remains controversial 1.